Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Inventory (2018 - 2025)

China SXT Pharmaceuticals has reported Inventory over the past 8 years, most recently at $114680.0 for Q3 2025.

  • For Q3 2025, Inventory fell 86.78% year-over-year to $114680.0; the TTM value through Sep 2025 reached $114680.0, down 86.78%, while the annual FY2025 figure was $828053.0, 4.18% up from the prior year.
  • Inventory for Q3 2025 was $114680.0 at China SXT Pharmaceuticals, down from $828053.0 in the prior quarter.
  • Over five years, Inventory peaked at $867233.0 in Q3 2024 and troughed at $7006.0 in Q3 2023.
  • A 5-year average of $503377.3 and a median of $711520.5 in 2022 define the central range for Inventory.
  • Biggest five-year swings in Inventory: plummeted 98.88% in 2023 and later soared 12278.43% in 2024.
  • Year by year, Inventory stood at $837447.0 in 2021, then dropped by 24.99% to $628186.0 in 2022, then plummeted by 98.88% to $7006.0 in 2023, then soared by 12278.43% to $867233.0 in 2024, then crashed by 86.78% to $114680.0 in 2025.
  • Business Quant data shows Inventory for SXTC at $114680.0 in Q3 2025, $828053.0 in Q1 2025, and $867233.0 in Q3 2024.